Related Experiment Video
Updated: Dec 28, 2025
Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs
Published on: December 24, 2015
Immunomodulatory benefits of mesenchymal stem cells treated with Caffeine in adjuvant-induced arthritis
Elham Moases Ghaffary1, Seyyed Meysam Abtahi Froushani1
1Department of Microbiology, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.
Purpose:
We intend to assess the effect of the conditioned medium of Caffeine pulsed MSCS in the amelioration of rheumatoid arthritis (RA)-afflicted rats.
Methods:
MSCs were incubated with 0, 0.1, 0.5 or 1 mM Caffeine for 2 weeks. RA was induced by the injection of complete Freund's adjuvant (CFA) into the base of the tail of Wistar rats. According to in vitro studies, RA rats were intraperitoneally treated with MSCs, Caffeine (0.5 mM) pulsed MSCs or vehicle on day 14 when all rats had shown signs of RA.
Results:
Our results suggest that the least effective dose concentration of Caffeine that can induce potent anti-inflammatory property in the MSC population is 0.5 mM. Without any significant impact on the vitality or MScs' marker, Caffeine at this concentration could induce lower levels of IFN-γ, IL-6, and IL-1β and a higher level of IDO, TGF-β, and IL-10 compared to other groups. Therefore, MSCs pulsed with Caffeine at 0.5 mM concentration was selected for in vitro studies. Caffeine pulsed MSCs could reduce the severity of the disease and improve weight-gaining more profoundly than treatment with MSCs alone. Furthermore, Caffeine pulsed MSCs caused a significant reduction in the serum levels C-reactive protein, Nitric oxide, Myeloperoxidase, TNF-α and conversely led a significant increase in the levels of IL-10 more prominent than the similar findings brought about by MSCs alone.
Conclusion:
In general, caffeine-treated MSCs may be a promising strategy for cell-based therapy of RA.
Insights
Caffeine-pulsed mesenchymal stem cells (MSCs) show potent anti-inflammatory effects, significantly reducing rheumatoid arthritis (RA) severity in rats. This cell-based therapy offers a promising new strategy for treating RA.
Area of Science:
- Immunology
- Regenerative Medicine
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
- Mesenchymal stem cells (MSCs) have immunomodulatory properties that make them a potential therapeutic agent for RA.
- Caffeine is known for its anti-inflammatory effects, but its role in modulating MSCs for RA treatment is underexplored.
Purpose of the Study:
- To evaluate the efficacy of conditioned medium from caffeine-pulsed MSCs in ameliorating rheumatoid arthritis (RA) in a rat model.
- To determine the optimal caffeine concentration for enhancing MSCs' anti-inflammatory properties.
Main Methods:
- MSCs were incubated with varying concentrations of caffeine (0-1 mM) for two weeks.
- Rheumatoid arthritis was induced in Wistar rats using complete Freund's adjuvant (CFA).
- RA rats were treated with MSCs, caffeine-pulsed MSCs (0.5 mM), or vehicle control via intraperitoneal injection.
Main Results:
- Caffeine at 0.5 mM significantly enhanced MSCs' anti-inflammatory profile, increasing IDO, TGF-β, and IL-10, while decreasing IFN-γ, IL-6, and IL-1β, without affecting MSC viability.
- Caffeine-pulsed MSCs demonstrated superior reduction in RA severity and improved weight gain compared to MSCs alone.
- Treatment with caffeine-pulsed MSCs led to significant reductions in serum C-reactive protein, nitric oxide, myeloperoxidase, and TNF-α, alongside a notable increase in IL-10 levels.
Conclusions:
- Caffeine-pulsed MSCs represent a promising cell-based therapeutic strategy for rheumatoid arthritis.
- The optimal concentration of 0.5 mM caffeine effectively enhances MSCs' immunomodulatory capacity for RA treatment.
- This approach offers a novel avenue for developing more effective treatments for RA.
More Related Videos
10:40Author Spotlight: Insight Into Advances in Prion Diseases Research
Published on: August 11, 2023
07:45Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
Published on: September 1, 2017
